newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia

  • IGC Pharma announced the completion of the six-week treatment phase for its 170-participant CALMA Phase 2 trial in November 2026.
  • All participants with agitation in Alzheimer's dementia across sites in the US & Canada completed dosing, assessments, & required visits.
  • The trial exceeded its original enrollment target of 146 participants by enrolling 170 participants.
  • CALMA is a randomized, double-blind, placebo-controlled study evaluating the investigational oral liquid IGC-AD1.
  • The primary endpoint measures changes in agitation from baseline to Week 6 using the Cohen-Mansfield Agitation Inventory.
  • Additional assessments include cognition, caregiver burden, safety, tolerability, & biomarkers.
  • The company is currently finalizing data verification, reconciliation, & quality-control activities ahead of database lock.
  • Treatment assignments will be unblinded followed by independent statistical analysis under the study's plan.
  • Topline results are anticipated during the December 2026/January 2027 timeframe, subject to clinical trial & data-management uncertainties.
  • IGC Pharma is a clinical-stage biotechnology company developing IGC-AD1 for Alzheimer's agitation & AI-enabled technologies for drug discovery.
Company
IGC Pharma, Inc.
Keywords
Biotechnology, Company Update